Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159627 · ClinicalTrials.gov registry record · Phase 2
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
A Phase 2 study of Heart Failure, Congestive, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 10
- Study locations
NCT00159627: Completed Phase 2 study of Heart Failure, Congestive, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00159627 is a Phase 2 study of Heart Failure, Congestive that has completed, run by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 52 participants, below the 674-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00159627, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.
Conditions Studied
Interventions
- DRUG KW-3902IV
Study Locations (10)
Massachusetts
- - Ayer
- - Boston
California
- - Stanford
District of Columbia
- - Washington D.C.
Florida
- - Sarasota
Maryland
- - Baltimore
New Jersey
- - Newark
Pennsylvania
- - Philadelphia
South Carolina
- - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00159627 record still lists
NCT00159627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 674-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which KW-3902IV is the first listed.
NCT00159627 lists 10 locations in 9 states (Massachusetts, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00159627 about?
NCT00159627 is a clinical study titled "Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).". The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.
What is the current status of trial NCT00159627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-08.
What conditions does trial NCT00159627 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT00159627?
The interventions under investigation include: KW-3902IV (DRUG).
Who is sponsoring clinical trial NCT00159627?
This trial is sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00159627 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00159627's enrollment target sits among peer trials
52 29th of 39 higher than 11 of 39 other Heart Failure, Congestive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise After an ICD
COMPLETED · Phase 2
-
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
COMPLETED · Phase 2
-
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
COMPLETED · Phase 2
-
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
COMPLETED · Phase 2
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia